In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus

Diagnostic Microbiology and Infectious Disease

Volumn 57, Issue 4, 2007, Pages 413-418

  LaPlante, Kerry L ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Colonize; Decolonize; Gentamicin; Lysostaphin; Mupirocin; Tea tree oil; Vancomycin methicillin resistant Staphylococcus aureus

Indexed keywords

LYSOSTAPHIN; METICILLIN; PSEUDOMONIC ACID; TEA TREE OIL;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; DRUG ANTAGONISM; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; LYSOSTAPHIN; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MUPIROCIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEA TREE OIL;

EID: 33947705277     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.09.007     Document Type: Article

References (31)

1. Bloom B.S., Fendrick A.M., Chernew M.E., and Patel P. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis. Am. J. Kidney Dis. 27 (1996) 687-694
2. Bonapace C.R., Bosso J.A., Friedrich L.V., and White R.L. Comparison of methods of interpretation of checkerboard synergy testing. Diagn. Microbiol. Infect. Dis. 44 (2002) 363-366
3. Caelli M., Porteous J., Carson C.F., Heller R., and Riley T.V. Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. 46 (2000) 236-237
4. Carson C.F., and Riley T.V. Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia. J. Appl. Bacteriol. 78 (1995) 264-269
5. Cespedes C., Said-Salim B., Miller M., Lo S.H., Kreiswirth B.N., Gordon R.J., Vavagiakis P., Klein R.S., and Lowy F.D. The clonality of Staphylococcus aureus nasal carriage. J. Infect. Dis. 191 (2005) 444-452
6. Claassen M., Nouwen J., Fang Y., Ott A., Verbrugh H., Hofman A., van Belkum A., and Uitterlinden A. Staphylococcus aureus nasal carriage is not associated with known polymorphism in the Vitamin D receptor gene. FEMS Immunol. Med. Microbiol. 43 (2005) 173-176
7. Climo M.W., Ehlert K., and Archer G.L. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45 (2001) 1431-1437
8. Cookson B.D. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J. Antimicrob. Chemother. 41 (1998) 11-18
9. Davis K.A., Stewart J.J., Crouch H.K., Florez C.E., and Hospenthal D.R. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin. Infect. Dis. 39 (2004) 776-782
10. den Hollander J.G., Mouton J.W., and Verbrugh H.A. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. Antimicrob. Agents Chemother. 42 (1998) 744-748
11. Doebbeling B.N., Reagan D.R., Pfaller M.A., Houston A.K., Hollis R.J., and Wenzel R.P. Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Arch. Intern. Med. 154 (1994) 1505-1508
12. Dombros N., Dratwa M., Feriani M., Gokal R., Heimburger O., Krediet R., Plum J., Rodrigues A., Selgas R., Struijk D., and Verger C. European best practice guidelines for peritoneal dialysis. 3 Peritoneal access. Nephrol. Dial. Transplant. 20 Suppl 9 (2005) ix8-ix12
13. Ellis M.W., Hospenthal D.R., Dooley D.P., Gray P.J., and Murray C.K. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin. Infect. Dis. 39 (2004) 971-979
14. Jernigan J.A. Eradicating nasal carriage of staphylococcus aureus as a strategy for preventing health care-associated infections in nonsurgical patients. Curr. Infect. Dis. Rep. 6 (2004) 417-419
15. Kokai-Kun J.F., Walsh S.M., Chanturiya T., and Mond J.J. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob. Agents Chemother. 47 (2003) 1589-1597
16. Kresken M., Hafner D., Schmitz F.J., and Wichelhaus T.A. Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. Int. J. Antimicrob. Agents 23 (2004) 577-581
17. LaPlante K.L., and Rybak M.J. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn. Microbiol. Infect. Dis. 50 (2004) 125-130
18. Laupland K.B., and Conly J.M. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin. Infect. Dis. 37 (2003) 933-938
19. Luzar M.A., Coles G.A., Faller B., Slingeneyer A., Dah G.D., Briat C., Wone C., Knefati Y., Kessler M., and Peluso F. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N. Engl. J. Med. 322 (1990) 505-509
20. Maraha B., van Halteren J., Verzijl J.M., Wintermans R.G., and Buiting A.G. Decolonization of methicillin-resistant Staphylococcus aureus using oral vancomycin and topical mupirocin. Clin. Microbiol. Infect. 8 (2002) 671-675
21. Mody L., Kauffman C.A., McNeil S.A., Galecki A.T., and Bradley S.F. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 37 (2003) 1467-1474
22. NCCLS. National Committee for Clinical Laboratory Standards. 2003. Supplemental tables M100-S13 (2003)
23. NCCLS. National Committee for Clinical Laboratory Standards. 2003. Approved standard M7-A6. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (2004)
24. Pearson R.D., Steigbigel R.T., Davis H.T., and Chapman S.W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob. Agents Chemother. 18 (1980) 699-708
25. Perl T.M., Cullen J.J., Wenzel R.P., Zimmerman M.B., Pfaller M.A., Sheppard D., Twombley J.J., French P.P., and Herwaldt L.A. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N. Engl. J. Med. 346 (2002) 1871-1877
26. Rybak M.J., Cha K.L., Cheung R., Meka M., and Kaatz G. Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. Diagn. Microbiol. Infect. Dis. 51 (2005) 119-125
27. Rybak M., and LaPlante J. Community associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy 25 (2005) 74-85
28. Shrestha N.K., Banbury M.K., Weber M., Cwynar R.E., Lober C., Procop G.W., Karafa M.T., and Gordon S.M. Safety of targeted perioperative mupirocin treatment for preventing infections after cardiac surgery. Ann. Thorac. Surg. 81 (2006) 2183-2188
29. Taylor P.C., Schoenknecht F.D., Sherris J.C., and Linner E.C. Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: influence and significance of technical factors. Antimicrob. Agents Chemother. 23 (1983) 142-150
30. von Eiff C., Becker K., Machka K., Stammer H., and Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N. Engl. J. Med. 344 (2001) 11-16
31. Wertheim H.F., Vos M.C., Ott A., Voss A., Kluytmans J.A., Vandenbroucke-Grauls C.M., Meester M.H., van Keulen P.H., and Verbrugh H.A. Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study. Ann. Intern. Med. 140 (2004) 419-425